RxDoctor Payments Data

William Long, MD

Vascular & Interventional Radiology · Alexandria, LANPI 1992767404

Payments from drug & device makers

What this record shows

This record is dominated by other: $84,273 of the $91,729 with a category attached, or 91.9%. Angiodynamics, Inc. accounts for 98.9% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2022 at $44,514 and has fallen 87.4% since, to $5,599 in 2025.

$91,729in general payments, 2019–2025

Across 173 payments — averaging $530.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$91K
  • Boston Scientific$234
  • Cardiovascular Systems Inc.$176
  • Medtronic$147
  • Veryan Medical Incorporated$143
  • Terumo Medical Corporation$100
  • plus $203 from 6 others

What the payments were for

  • Travel & lodging$9341%
  • Food & beverage$6,5227%
  • Other$84,27392%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Angiodynamics, Inc.144$90,727
Boston Scientific5$234
Cardiovascular Systems Inc.2$176
Medtronic(2 entities)8$147
Veryan Medical Incorporated2$143
Terumo Medical Corporation2$100
Philips North America LLC3$64
Nipro Medical Corporation2$61
Johnson & Johnson2$26
Cashflow Solutions, LLC1$26
Abbott1$13
Biocompatibles, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$91,729 in reported general payments places this provider in the 85th percentile of 42 vascular & interventional radiology providers in Louisiana.

See all vascular & interventional radiology providers in Louisiana

Medicare billing

Part B allowed, 2024
$2,289,382
Medicare patients
116
Services billed
2,270

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban207$165,375
ClopidogrelClopidogrel Bisulfate230$2,176

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$26$165,375207 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 42 vascular & interventional radiology providers in Louisiana.

Other vascular & interventional radiology in Alexandria

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →